Evidence map›Paper›PMID 27262508›Full record

ArticleTrends in biotechnology2016

Revisiting the 'One Material Fits All' Rule for Cancer Nanotherapy.

João Conde, Nuria Oliva, Natalie Artzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

João CondeMassachusetts Institute of Technology, Institute for Medical Engineering and Science, Cambridge, MA, USA; School of Engineering and Materials Science, Queen Mary University of London, London, UK. Electronic address: jdconde@mit.edu.
Nuria OlivaMassachusetts Institute of Technology, Institute for Medical Engineering and Science, Cambridge, MA, USA.
Natalie ArtziMassachusetts Institute of Technology, Institute for Medical Engineering and Science, Cambridge, MA, USA; Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: nartzi@mit.edu.

Funding

Organ Design and Engineering Training Program (ODET Program)T32EB016652 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2014 to 2023
$3.5M
NIBIB NIH HHS T32 EB016652
6 · The paper itself

Abstract

The promise of (nano)biomaterials for the treatment of cancer can only be realized following a comprehensive scrutiny of the tumor microenvironment. The generic use of 'inert' vehicles that deliver a specific cargo to treat a range of cancer types and disease states obeys the 'one material fits all' rule. However, this approach leads to suboptimal and unpredictable clinical outcomes. The key factors constructing the tumor milieu should guide the design of disease-responsive materials. Given the growing availability of nanomaterials for cancer therapy, a material that responds to each patient's needs and, hence, reacts in a graded manner based on disease cues, would pave the way to precision materials for cancer therapy.

Indexed as

AnimalsAntineoplastic AgentsCell SurvivalDrug DesignHumansModels, BiologicalNanoparticlesNeoplasmsTumor MicroenvironmentAntineoplastic Agents

Identifiers

PMID27262508
PMCPMC6527107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.